Novel 2019 coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) and coronavirus disease 2019 (COVID-19), the respiratory syndrome it causes, have shaken the world to its core by infecting and claiming the lives of many people since originating in December 2019 in Wuhan, China. World Health Organization and several states have declared a pandemic situation and state of emergency, respectively. As there is no treatment for COVID-19, several research institutes and pharmaceutical companies are racing to find a cure. Advances in computational approaches have allowed the screening of massive antiviral compound libraries to identify those that may potentially work against SARS-CoV-2. Antiviral agents developed in the past to combat other viruses are being repurposed. At the same time, new vaccine candidates are being developed and tested in preclinical/clinical settings. This review provides a detailed overview of select repurposed drugs, their mechanism of action, associated toxicities, and major clinical trials involving these agents.
ZhuNZhangDWangWLiXYangBSongJZhaoXHuangBShiWLuR.A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med2020;
382:727–33
2.
DongEDuHGardnerL.An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis2020;
20:533–4
3.
JogalekarMPVeerabathiniAGangadaranP.Novel 2019 coronavirus: genome structure, clinical trials, and outstanding questions. Exp Biol Med (Maywood)2020;
245:964–9
4.
LuRZhaoXLiJNiuPYangBWuHWangWSongHHuangBZhuN.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet2020;
395:565–74
5.
SandersJMMonogueMLJodlowskiTZCutrellJB.Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA2020;
323:1824–36
6.
BeigelJHTomashekKMDoddLEMehtaAKZingmanBSKalilACHohmannEChuHYLuetkemeyerAKlineS.Remdesivir for the treatment of Covid-19. N Engl J Med2020;
383:1813–26
7.
LoMKFeldmannFGaryJMJordanRBannisterRCroninJPatelNRKlenaJDNicholSTCihlarT.Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med2019;
11:eaau9242
8.
MadelainVBaizeSJacquotFReynardSFizetABarronSSolasCLacarelleBCarbonnelleCMentréF.Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun2018;
9:4013
9.
de WitEFeldmannFCroninJJordanROkumuraAThomasTScottDCihlarTFeldmannH.Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A2020;
117:6771–6
10.
SheahanTPSimsACLeistSRSchäferAWonJBrownAJMontgomerySAHoggABabusisDClarkeMO.Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun2020;
11:222
11.
SiegelDHuiHCDoerfflerEClarkeMOChunKZhangLNevilleSCarraELewWRossB.Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem2017;
60:1648–61
12.
Al-TawfiqJAAl-HomoudAHMemishZA.Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis2020;
34:101615
13.
WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoG.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res2020;
30:269–71
14.
KalilACPattersonTFMehtaAKTomashekKMWolfeCRGhazaryanVMarconiVCRuiz-PalaciosGMHsiehLKlineS.Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021;384:795–807
15.
GoldmanJDLyeDCHuiDSMarksKMBrunoRMontejanoRSpinnerCDGalliMAhnM-YNahassRG.Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med2020;
383:1827–37
WHO Solidarity Trial Consortium.Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. N Engl J Med2020;
384:497–511
18.
SavarinoABoelaertJRCassoneAMajoriGCaudaR.Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis2003;
3:722–7
19.
DevauxCARolainJ-MColsonPRaoultD.New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?Int J Antimicrob Agents2020;
55:105938
20.
ZhouDDaiS-MTongQ.COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother2020;
75:1667–70
21.
DelvecchioRHigaLMPezzutoPValadãoALGarcezPPMonteiroFLLoiolaECDiasAASilvaFJAliotaMT.Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses2016;
8:322
22.
FariasKJSMachadoPRLda FonsecaBAL.Chloroquine inhibits dengue virus type 2 replication in vero cells but not in C6/36 cells. ScientificWorldJournal2013;
2013:282734
23.
OoiEEChewJSWLohJPChuaRC.In vitro inhibition of human influenza a virus replication by chloroquine. Virol J2006;
3:39
24.
TsaiW-PNaraPLKungH-FOroszlanS.Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses1990;
6:481–9
25.
YaoXYeFZhangMCuiCHuangBNiuPLiuXZhaoLDongESongC.In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis2020;
71:732–9
26.
GaoJTianZYangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends2020;
14:72–3
27.
GautretPLagierJ-CParolaPMeddebLMailheMDoudierBCourjonJGiordanengoVVieiraVEDupontHT.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents2020;
56:105949
28.
Chen J, LD, LL, LP, Xu Q XL, Ling Y, Huang D Song S, Zhang D.A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci)2020;
49:215–9
29.
BoulwareDRPullenMFBangdiwalaASPastickKALofgrenSMOkaforECSkipperCPNasceneAANicolMRAbassiM.A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med2020;
383:517–25
30.
CavalcantiABZampieriFGRosaRGAzevedoLCVeigaVCAvezumADamianiLPMarcadentiAKawano-DouradoLLisboaT.Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med2020;
383:2041–52
31.
RECOVERY Collaborative Group.Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med2020;
383:2030–40
32.
KalilAC.Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA2020;
323:1897–8
33.
LuZKYuanJLiMSuttonSSRaoGAJacobSBennettCL.Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf2015;
14:295–303
34.
ThomsonKNachlisH.Emergency use authorizations during the COVID-19 pandemic: lessons from hydroxychloroquine for vaccine authorization and approval. JAMA2020;
324:1282–3
35.
ChanJF-WYaoYYeungM-LDengWBaoLJiaLLiFXiaoCGaoHYuP.Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis2015;
212:1904–13
36.
OldfieldVPloskerGL.Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs2006;
66:1275–99
37.
Cunha A, Hagemann C, Simoes R, Oliveira-Filho R, Simões M, Soares J Jr, Maciel G, Oliveira F, Amed A, Kulay L Jr.Effects of lopinavir–ritonavir combined therapy during the rat pregnancy: morphological and biochemical aspects. Eur J Obstet Gynecol Reprod Biol2007;
133:60–3
38.
De WildeAHJochmansDPosthumaCCZevenhoven-DobbeJCVan NieuwkoopSBestebroerTMVan Den HoogenBGNeytsJSnijderEJ.Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother2014;
58:4875–84
39.
ChoyK-TWongAY-LKaewpreedeePSiaS-FChenDHuiKPYChuDKWChanMCWCheungPP-HHuangX.Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res2020;
178:104786
40.
MuralidharanNSakthivelRVelmuruganDGromihaMM.Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Str Dyn2020;1–6
41.
CaoBWangYWenDLiuWWangJFanGRuanLSongBCaiYWeiM.A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med2020;
382:1787–99
42.
ArabiYMAsiriAYAssiriAMBalkhyHHAl BshabsheAAl JeraisyMMandourahYAzzamMHBin EshaqAMAl JohaniS.Interferon beta-1b and lopinavir–ritonavir for Middle East respiratory syndrome. N Engl J Med2020;
383:1645–56
43.
QueTWongVYuenK.Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J2003;
9:399–406
44.
YaoTTQianJDZhuWYWangYWangGQ.A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol2020;
92:556–63
45.
CooperCVan HeeswijkRGallicanoKCameronD.A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis2003;
36:1585–92
46.
WuCChenXCaiYZhouXXuSHuangHZhangLZhouXDuCZhangY.Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med2020;
180:934–43
47.
KakudaTNVan De CasteeleTPetrovicRNeujensMSalihHOpsomerMHoetelmansRM.Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther2014;
19:597–606
48.
FurutaYKomenoTNakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci2017;
93:449–63
49.
ShirakiKDaikokuT.Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther2020;
209:107512
50.
AgrawalURajuRUdwadiaZF.Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India2020;
76:370–6
51.
YanaiH.Favipiravir: a possible pharmaceutical treatment for COVID-19. J Endocrinol Metab2020;
10:33–4
52.
ShresthaDBBudhathokiPKhadkaSShahPBPokharelNRashmiP.Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J2020;
17:141
53.
ChuCChengVHungIWongMChanKChanKKaoRPoonLWongCGuanY.Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax2004;
59:252–6
54.
Al-TawfiqJAMomattinHDibJMemishZA.Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis2014;
20:42–6
55.
OmraniASSaadMMBaigKBahloulAAbdul-MatinMAlaidaroosAYAlmakhlafiGAAlbarrakMMMemishZAAlbarrakAM.Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis2014;
14:1090–5
56.
SpanakisNTsiodrasSHaagmansBLRajVSPontikisKKoutsoukouAKoulourisNGOsterhausADKoopmansMPTsakrisA.Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents2014;
44:528–32
57.
FooladFAitkenSLShigleTLPrayagAGhantojiSAriza-HerediaEChemalyRF.Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis2019;
68:1641–9
58.
BojkovaDKlannKKochBWideraMKrauseDCiesekSCinatlJMünchC.Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature2020;
583:469–72
59.
StockmanLJBellamyRGarnerP.SARS: systematic review of treatment effects. PLoS Med2006;
3:e343
60.
ArabiYMShalhoubSMandourahYAl-HameedFAl-OmariAAl QasimEJoseJAlraddadiBAlmotairiAAl KhatibK.Ribavirin and interferon therapy for critically ill patients with Middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis2020;
70:1837–44
61.
AltinbasSHolmesJAAltinbasA.Hepatitis C virus infection in pregnancy: an update. Gastroenterol Nurs2020;
43:12–21
62.
KadamRUWilsonIA.Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol. Proc Natl Acad Sci U S A2017;
114:206–14
63.
BoriskinYLenevaIPecheurE-IPolyakS.Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem2008;
15:997–1005
64.
HaviernikJŠtefánikMFojtíkováMKaliSTordoNRudolfIHubálekZEyerLRuzekD.Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses2018;
10:184
65.
KhamitovRLoginovaSShchukinaVBorisevichSMaksimovVShusterA.Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol2008;
53:9–13
66.
WangZYangBLiQWenLZhangR.Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis2020;
71:769–77
67.
MosconaA.Neuraminidase inhibitors for influenza. N Engl J Med2005;
353:1363–73
68.
LenevaIARobertsNGovorkovaEAGoloubevaOGWebsterRG.The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against a/Hong Kong/156/97 (H5N1) and a/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res2000;
48:101–15
69.
TumpeyTMGarcía-SastreAMikulasovaATaubenbergerJKSwayneDEPalesePBaslerCF.Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A2002;
99:13849–54
70.
DaviesBE.Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother2010;
65:ii5–ii10
71.
TooveySPrinssenEPRaynerCRThakrarBTDutkowskiRKoernerAChuTSirzen-ZelenskayaABritschgiMBansodS.Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther2012;
29:826–48
72.
HoffmanKBDemakasAErdmanCBDimbilMDoraiswamyPM.Neuropsychiatric adverse effects of oseltamivir in the FDA adverse event reporting system, 1999-2012. BMJ2013;
347:f4656
73.
ZhouYVedanthamPLuKAgudeloJCarrionRJrNunneleyJWBarnardDPöhlmannSMcKerrowJHRensloAR.Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res2015;
116:76–84
74.
HoffmannMKleine-WeberHSchroederSKrügerNHerrlerTErichsenSSchiergensTSHerrlerGWuN-HNitscheA.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell2020;
181:271–80.e8
75.
UnoY.Camostat mesilate therapy for COVID-19. Intern Emerg Med2020;
15:1577–8
76.
RamseyMLNuttallJHartPA.A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). Trials2019;
20:501
77.
GurwitzD.Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res2020;
81:537–40
78.
ImaiYKubaKRaoSHuanYGuoFGuanBYangPSaraoRWadaTLeong-PoiH.Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature2005;
436:112–6
79.
FuruhashiMMoniwaNMitaTFuseyaTIshimuraSOhnoKShibataSTanakaMWatanabeYAkasakaH.Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens2015;
28:15–21
80.
KlimasJOlvedyMOchodnicka ‐MackovicovaKKruzliakPCacanyiovaSKristekFKrenekPOchodnickyP.Perinatally administered losartan augments renal ACE 2 expression but not cardiac or renal mas receptor in spontaneously hypertensive rats. J Cell Mol Med2015;
19:1965–74
81.
CohenJBHanffTCWilliamPSweitzerNRosado-SantanderNRMedinaCRodriguez-MoriJERennaNChangTICorrales-MedinaV.Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med2021;9:275–84
82.
LopesRDMacedoAVSilvaPMoll-BernardesRJdos SantosTMMazzaLFeldmanAArrudaGDAS, DCCamilettiAS.Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA2021;
325:254–64
83.
TurnerJMKodaliR.Should angiotensin-converting enzyme inhibitors ever be used for the management of hypertension?Curr Cardiol Rep2020;
22:95
84.
KhanABenthinCZenoBAlbertsonTEBoydJChristieJDHallRPoirierGRoncoJJTidswellM.A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care2017;
21:234
85.
ZoufalyAPoglitschMAberleJHHoeplerWSeitzTTraugottMGriebAPawelkaELaferlHWenischC.Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med2020;
8:1154–8
86.
RussellCDMillarJEBaillieJK.Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet2020;
395:473–5
87.
MishraGPMulaniJ.Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir Med2021;
9:e8
88.
PrescottHCRiceTW.Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. JAMA2020;
324:1292–5
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
